Summary
AI claims largely address metoprolol in general/other formulations and economic/manufacturer topics not supported by the provided FDA label excerpts for metoprolol tartrate injection; many indicated uses described are absent from the provided label.
Category Scores
Accurate Statements
The prices of metoprolol vary significantly depending on the pharmacy, location, and insurance coverage.
Not supported or mentioned in the provided metoprolol tartrate injection label excerpts (these excerpts contain no pricing/market statements).
Unsupported Statements
Metoprolol is prescribed to treat high blood pressure.
The provided label excerpts for metoprolol tartrate injection indicate only acute myocardial infarction; no hypertension indication is present.
Metoprolol is prescribed to treat angina.
Not supported by the provided indication excerpt (acute myocardial infarction only).
Metoprolol is prescribed to treat heart failure.
The label excerpt discusses worsening cardiac failure as a warning/adverse reaction context, not an approved indication for heart failure.
Metoprolol is prescribed for certain arrhythmias.
Arrhythmia indication is not present in the provided indication excerpt.
Generic metoprolol has significantly lower prices compared to the brand-name version Lopressor.
Pricing comparisons are not addressed in the provided label excerpts.
Generic versions of metoprolol have remained on the market for many years.
Market longevity is not addressed in the provided label excerpts.
Generic versions of metoprolol have led to increased price competition and lower costs for patients.
Health economics/patient cost outcomes are not addressed in the provided label excerpts.
The prices of metoprolol vary significantly depending on the pharmacy, location, and insurance coverage.
Pricing variability is not addressed in the provided label excerpts.
A study found metoprolol 25 mg tablet prices at Walmart, CVS Pharmacy, and Walgreens ranged from $10 to $30 depending on pharmacy and location.
No study or pricing data is included in the provided label excerpts; also the label excerpts provided are for IV injection, not 25 mg tablets.
Multiple manufacturers producing generic metoprolol have led to increased competition resulting in lower prices and price discounts.
No manufacturer/competition/discount information is included in the provided label excerpts.
Teva Pharmaceuticals, Actavis, and Mylan have offered low-cost versions of metoprolol.
No manufacturer-specific pricing/availability is included in the provided label excerpts.
Pfizer implemented manufacturer-preferred pricing (MPP) programs.
No information about MPP programs or specific company actions is included in the provided label excerpts.
Manufacturer-preferred pricing (MPP) programs offer discounted prices to certain customers such as hospital systems.
No information about MPP programs is included in the provided label excerpts.
Manufacturer-preferred pricing (MPP) programs are offered in exchange for purchase commitments and rebates.
No information about MPP program structure is included in the provided label excerpts.
Patients may be eligible for patient assistance programs (PAPs) or discounts to reduce out-of-pocket costs for metoprolol.
No information about patient assistance programs or discounts is included in the provided label excerpts.
The patent for Lopressor (metoprolol tartrate) expires on an inserted expiration date.
The provided label excerpts contain no patent or expiration information; the phrase 'inserted expiration date' is not label-supported.
Contradictions
Important Omissions
Dose, bolus schedule, monitoring requirements, and transition to oral metoprolol after IV administration (3 x 5 mg bolus ~2 minutes apart; monitor BP/HR/ECG) for metoprolol tartrate injection.
Importance:
Moderate
Key contraindications for metoprolol tartrate injection (e.g., heart rate <45/min, specific conduction blocks, SBP <100 mmHg, decompensated cardiac failure).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided AI statements are primarily about general indications and pricing/market access, not dosing or safety-critical instructions from the label. However, incorrect implication of broader approved uses could lead to label-mismatch, which can affect appropriate selection if used as clinical guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most medical indication claims (hypertension, angina, heart failure, arrhythmias) are not supported by the provided prescribing information excerpt for metoprolol tartrate injection, which specifically addresses acute myocardial infarction in hemodynamically stable patients with oral maintenance therapy.
Suggested Improvement
Limit medical claims to the provided label indication (acute myocardial infarction with oral metoprolol maintenance therapy) and remove or clearly separate non-label economic/market assertions (pricing, MPP, PAP, patents) that are not present in the FDA label excerpts.